We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

114 hedge funds and large institutions have $1.04B invested in Audentes Therapeutics, Inc in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 50 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

213% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 16

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

36% more capital invested

Capital invested by funds: $768M → $1.04B (+$274M)

28% more funds holding

Funds holding: 89 → 114 (+25)

12% less call options, than puts

Call options by funds: $2.1M | Put options by funds: $2.38M

Holders
114
Holders Change
+25
Holders Change %
+28.09%
% of All Funds
2.61%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
36
Increased
50
Reduced
16
Closed
9
Calls
$2.1M
Puts
$2.38M
Net Calls
-$279K
Net Calls Change
-$279K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$141M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.1M
3
BlackRock
BlackRock
New York
+$20.4M
4
Victory Capital Management
Victory Capital Management
Texas
+$15.6M
5
State Street
State Street
Massachusetts
+$14.2M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$20.6M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$17.8M
3
Citadel Advisors
Citadel Advisors
Florida
-$11.5M
4
DCM
Driehaus Capital Management
Illinois
-$5.92M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$4.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCP
26
Tourbillon Capital Partners
New York
$8.89M +$10M +295,754 New
EAM
27
Eventide Asset Management
Massachusetts
$8.11M +$1.52M +45,000 +20%
Morgan Stanley
28
Morgan Stanley
New York
$7.62M +$6.41M +189,480 +295%
Northern Trust
29
Northern Trust
Illinois
$7.48M +$1.49M +44,102 +22%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$6.92M +$952K +28,126 +14%
Adage Capital Partners
31
Adage Capital Partners
Massachusetts
$6.76M -$17.8M -525,000 -70%
Millennium Management
32
Millennium Management
New York
$6.35M +$7.16M +211,348 New
SIM
33
Spark Investment Management
New York
$5.78M +$3.31M +97,900 +104%
OM
34
Opaleye Management
Massachusetts
$5.71M -$677K -20,000 -10%
AG
35
Artal Group
Luxembourg
$4.51M -$1.69M -50,000 -25%
JP Morgan Chase
36
JP Morgan Chase
New York
$3.45M -$251K -7,403 -6%
Deutsche Bank
37
Deutsche Bank
Germany
$3.23M +$1.93M +56,949 +112%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$2.9M +$482K +14,236 +17%
SFM
39
Sphera Funds Management
Israel
$2.85M – – –
Axa
40
Axa
France
$2.29M +$2.58M +76,325 New
Renaissance Technologies
41
Renaissance Technologies
New York
$2.24M +$714K +21,100 +39%
SCA
42
Secor Capital Advisors
New York
$1.83M +$1.52M +44,871 +282%
USAA
43
United Services Automobile Association
Texas
$1.78M +$2.01M +59,328 New
CS
44
Candriam SCA
Luxembourg
$1.74M +$1.96M +58,000 New
EIM
45
Essex Investment Management
Massachusetts
$1.73M -$406K -11,988 -17%
Allianz Asset Management
46
Allianz Asset Management
Germany
$1.68M +$1.89M +55,824 New
UOC
47
UBS O'Connor
Illinois
$1.66M +$1.86M +55,085 New
Invesco
48
Invesco
Georgia
$1.54M +$1.73M +51,242 New
UBS Group
49
UBS Group
Switzerland
$1.52M +$1.41M +41,696 +472%
TD Asset Management
50
TD Asset Management
Ontario, Canada
$1.49M +$99.3K +2,932 +6%
1
2
3 4 5

BOLD Hedge Fund Activity: Q1 2018 in Review

114 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q1 2018, worth a combined $1.04B — up 36% from $768M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new BOLD positions and 9 closed out — a net gain of 27 holders — while 50 added to existing stakes and 16 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $141M. The largest seller was OrbiMed, cutting an estimated $20.6M.

  • 114 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q1 2018, up from 89 in Q4 2017.
  • Funds reported $1.04B of Audentes Therapeutics, Inc stock for Q1 2018, up 36% quarter-over-quarter.
  • 36 funds opened new Audentes Therapeutics, Inc positions in Q1 2018 and 9 closed out, a net change of +27 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q1 2018 was Wellington Management Group, an estimated $141M added.
  • The largest Audentes Therapeutics, Inc seller in Q1 2018 was OrbiMed, an estimated $20.6M sold.

Based on aggregated 13F filings for Q1 2018.